Navigation Links
Neurocrine Biosciences Reports Third Quarter 2013 Results
Date:10/29/2013

SAN DIEGO, Oct. 29, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended September 30, 2013. For the third quarter of 2013, the Company reported a net loss of $11.1 million, or $0.17 loss per share, compared to a net loss of $3.1 million, or $0.05 loss per share, for the same period in 2012. For the nine months ended September 30, 2013, the Company reported a net loss of $35.4 million, or $0.53 loss per share, as compared to net loss of $4.5 million, or $0.07 loss per share, for the first nine months of last year. At September 30, 2013, the Company had cash, cash equivalents, investments and receivables of $158.5 million.

"Our Kinect study of NBI-98854 provided valuable information regarding dose response and endpoint assessment that we have incorporated into our Kinect 2 study and overall development plan. The Kinect 2 study has also recently completed enrollment and we will have the top-line results from this Phase IIb study in December," said Kevin Gorman, Ph.D., President and Chief Executive Officer of Neurocrine Biosciences. "Additionally, this past quarter AbbVie initiated the second Phase III study of elagolix in endometriosis and is scheduled to have top-line data from the initial elagolix Phase III endometriosis study in 2014. Elagolix is also progressing in a Phase IIb study of uterine fibroids patients."

Revenues for the third quarter of 2013 were $0.7 million, compared to $9.4 million for the same period in 2012. Revenues for the nine months ended September 30, 2013 were $2.2 million, compared to $31.2 million for the first nine months of 2012. The entire reduction in revenue from 2012 to 2013 is due to the successful completion of the sponsored research and development phases of the Company's license agreements with both AbbVi
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Reports Second Quarter 2013 Results
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
3. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
4. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
5. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
6. Neurocrine Biosciences Reports Third Quarter 2012 Results
7. Neurocrine Biosciences Reports Second Quarter 2012 Results
8. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
9. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
10. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
11. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... 2014) -- A new therapy developed by researchers ... College of Medicine and Columbia University Medical Center ... interventional cardiovascular disease treatment. , The researchers ... molecular therapy could selectively inhibit blood vessel re-narrowing ... procedure using a balloon catheter to open narrowed ...
(Date:8/18/2014)... UPTON, NYElectronic devices with unprecedented efficiency and ... materials that use built-in electric polarizations to ... magnets inside most popular data-driven technology. But ... stumbling blocks, including a curious habit of ... at the U.S. Department of Energy,s Brookhaven ...
(Date:8/18/2014)... Aug. 18, 2014 TNI BioTech, Inc. (OTC-BB: ... the manufacturing and marketing of innovative therapies for autoimmune ... is providing a second notice of TNI BioTech,s annual ... the announcement, Noreen Griffin , founder and CEO ... for your participation in the Annual Meeting. On behalf ...
(Date:8/16/2014)... 2014 Firms in the ... and advisory services to businesses, government bodies and ... services are highly diverse as operators assist a ... from geological and geophysical consulting services to risk ... past five years, the recovery of the Canadian ...
Breaking Biology Technology:Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 3
... 31 /PRNewswire-FirstCall/ - iNutrition, Inc., (http://www.inutrition.com ) today ... all natural line of nutrition bars. Fission Fruit ... in three varieties; Fission Fruit, Fission,Energy, and Fission ... fruits, Fission Bars have no refined sugar, no ...
... Ala., July 31 BioCryst,Pharmaceuticals (Nasdaq: BCRX ... results will be released on Thursday, August 7, ... call and Webcast at 8:30 a.m.,Eastern Time to ... on the,Company,s programs. The call will be led ...
... 31 Genta,Incorporated (OTC Bulletin Board: GNTA) announced ... 2008 financial results on Thursday, August,7, 2008. Genta ... audio,webcast to discuss these financial results and corporate ... the live call by dialing (877) 634-8606 (U.S.,and ...
Cached Biology Technology:iNutrition Launches New Fission Fruit Nutrition Bars 2BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008 2BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008 3Genta Announces Second Quarter 2008 Financial Results and Conference Call 2Genta Announces Second Quarter 2008 Financial Results and Conference Call 3
(Date:8/19/2014)... Eos: Long-Term Ecological Research and Network-Level Science, , Imagine ... wide range of ecosystems was responding to global changes ... powerful if it coupled multiple decades of information about ... and models from dozens of different ecosystem types. ... Long-Term Ecological Research (LTER) Network, which will soon celebrate ...
(Date:8/19/2014)... a biomarker strongly associated with basal-like breast cancer, ... many types of chemotherapy. The biomarker, a protein ... therapeutics designed to treat this often deadly cancer. ... The Cancer Genome Atlas, molecular biologists Curt M. ... and bioinformatics techniques to detect patterns of gene ...
(Date:8/19/2014)... Texas Health Science Center at San Antonio and The ... the awarding of more than $750,000 in grants through ... , Launched in 2003, SALSI is a model of ... health science center join forces for greater research and ... with a focus on public health issues and diseases ...
Breaking Biology News(10 mins):This week from AGU: Long-term ecological research, predicting cholera outbreaks 2Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3
... greater role in the disparity between the numbers of ... with the disease. A study by researchers at the ... the disparity was substantially reduced when comparing groups of ... environments. The results are published in the November 2008 ...
... RELEASE LEDs ... Chemical Society Researchers in Germany are describing a ... facial wrinkles. Their study, scheduled for the November 5 ... a bi-monthly journal, reports that high intensity visible light ...
... amyloid-b (Ab), builds up into fibrous plaques in the ... membrane microdomain to another to be cleaved, report Sakurai ... that Ab plaques are the direct cause of Alzheimer,s ... And working on this hypothesis, scientists are investigating just ...
Cached Biology News:Hypertension disparity linked to environment 2American Chemical Society Weekly PressPac Oct. 15, 2008 2American Chemical Society Weekly PressPac Oct. 15, 2008 3American Chemical Society Weekly PressPac Oct. 15, 2008 4American Chemical Society Weekly PressPac Oct. 15, 2008 5American Chemical Society Weekly PressPac Oct. 15, 2008 6American Chemical Society Weekly PressPac Oct. 15, 2008 7American Chemical Society Weekly PressPac Oct. 15, 2008 8
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
Parathyroid Hormone Receptor 2 [PTHR2]...
... Spin Columns contain a proprietary high-performance desalting ... desalting and protein-recovery characteristics compared to other ... as 25 g/ml of protein can be ... 95% retention of salts and other small ...
... caudal-related homeobox family, is an intestine-specific transcription ... in intestinal epithelial cells. It plays an ... phenotype of differentiated villus enterocytes as well ... Clone CDX2-88 reacts with a conserved epitope ...
Biology Products: